Scholarlink

<p>Clinical assessments of Parkinson’s disease (PD) focus on structured motor tasks, potentially underestimating real-world mobility impairment. Digital mobility outcomes (DMOs) from wearable devices, offer a promising alternative, but their clinical value remains unclear. This study reviewed the clinical utility of real-world DMOs in PD. Eight databases were searched (2000–2024). Eligibility included reports assessing real-world gait-based DMOs in PD. Study selection and data extraction were conducted independently by four reviewers. No meta-analysis was performed. Twenty-seven reports met inclusion criteria, reporting 21 DMOs. Walking speed was most common (92%), followed by step length (59%) and stride time (48%). Devices, assessment durations and walking bout definitions varied. DMOs differentiated PD from controls and real-world from supervised conditions. PD Subgroup analyses and associations with motor severity were inconsistent. Real-world DMOs offer valuable insight into PD mobility. Standardised protocols are needed for comparability. Further research should explore predictive utility and complex or composite DMOs. Trial Registration: PROSPERO 2025 CRD42021281213.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A systematic review of real-world gait-related digital mobility outcomes in Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月30日

查看全文
  • Cameron Kirk,
  • Emma Packer,
  • Ashley Polhemus,
  • Mhairi K. MacLean,
  • Harry Bailey,
  • Felix Kluge,
  • Heiko Gaßner,
  • Lynn Rochester,
  • Silvia Del Din,
  • Alison J. Yarnall

摘要

Clinical assessments of Parkinson’s disease (PD) focus on structured motor tasks, potentially underestimating real-world mobility impairment. Digital mobility outcomes (DMOs) from wearable devices, offer a promising alternative, but their clinical value remains unclear. This study reviewed the clinical utility of real-world DMOs in PD. Eight databases were searched (2000–2024). Eligibility included reports assessing real-world gait-based DMOs in PD. Study selection and data extraction were conducted independently by four reviewers. No meta-analysis was performed. Twenty-seven reports met inclusion criteria, reporting 21 DMOs. Walking speed was most common (92%), followed by step length (59%) and stride time (48%). Devices, assessment durations and walking bout definitions varied. DMOs differentiated PD from controls and real-world from supervised conditions. PD Subgroup analyses and associations with motor severity were inconsistent. Real-world DMOs offer valuable insight into PD mobility. Standardised protocols are needed for comparability. Further research should explore predictive utility and complex or composite DMOs. Trial Registration: PROSPERO 2025 CRD42021281213.